Moteur de recherche d’entreprises européennes
Financement de l’UE (5 838 576 €) : Validation clinique internationale de l’intelligence artificielle radiomique pour la planification du traitement du cancer du sein Hor28/07/2022 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
Validation clinique internationale de l’intelligence artificielle radiomique pour la planification du traitement du cancer du sein
Breast cancer is now the most common cancer worldwide, surpassing lung cancer in 2020 for the first time. It is responsible for almost 30% of all cancers in women and current trends show its increasing incidence. Neoadjuvant chemotherapy (NAC) has shown promise in reducing mortality for advanced cases, but the therapy is associated with a high rate of over-treatment, as well as with significant side effects for the patients. For predicting NAC respondents and improving patient selection, artificial intelligence (AI) approaches based on radiomics have shown promising preclinical evidence, but existing studies have mostly focused on evaluating model accuracy, all-too-often in homogeneous populations. RadioVal is the first multi-centre, multi-continental and multi-faceted clinical validation of radiomics-driven estimation of NAC response in breast cancer. The project builds on the repositories, tools and results of five EU-funded projects from the AI for Health Imaging (AI4HI) Network, including a large multi-centre cancer imaging dataset on NAC treatment in breast cancer. To test applicability as well as transferability, the validation with take place in eight clinical centres from three high-income EU countries (Sweden, Austria, Spain), two emerging EU countries (Poland, Croatia), and three countries from South America (Argentina), North Africa (Egypt) and Eurasia (Turkey). RadioVal will develop a comprehensive and standardised methodological framework for multi-faceted radiomics evaluation based on the FUTURE-AI Guidelines, to assess Fairness, Universality, Traceability, Usability, Robustness and Explainability. Furthermore, the project will introduce new tools to enable transparent and continuous evaluation and monitoring of the radiomics tools over time. The RadioVal study will be implemented through a multi-stakeholder approach, taking into account clinical and healthcare needs, as well as socio-ethical and regulatory requirements from day one.
| AIN Shams University | 145 500 € |
| Alexander Fleming SA | 184 466 € |
| Eibir Gemeinnutzige GmbH ZUR Forderung DER Erforschung DER Biomedizinischen Bildgebung | 271 875 € |
| Fundacion para La Investigacion del Hospital Universitario La Fe de La Comunidad Valenciana | 502 750 € |
| Gdanski Uniwersytet Medyczny | 318 750 € |
| Hacettepe Universitesi | 202 500 € |
| Idryma Technologias Kai Erevnas | 501 250 € |
| Karolinska Institutet | 399 985 € |
| Maggioli S.p.A. | 475 000 € |
| Medizinische Universitaet Wien | 250 000 € |
| NHG Finland Oy | 405 875 € |
| Quibim SL | 412 500 € |
| Shine 2Europe Lda. | 308 750 € |
| Sveuciliste U Zagrebu Medicinski Fakultet | 250 000 € |
| Universitat de Barcelona | 801 250 € |
| Universiteit Maastricht | 408 125 € |
https://cordis.europa.eu/project/id/101057699
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.